Long-acting (basal) insulin is a core part of diabetes care. It provides steady background insulin for people with type 1 diabetes and for many with type 2. Choosing a basal option, setting goals, and adjusting doses are clinical decisions that depend on age, comorbidities, and daily routines.
Prescription referral platforms help connect prescribers, patients, and dispensing pharmacies within regulated pathways. CanadianInsulin operates within this model. CanadianInsulin.com is a prescription referral platform. Where required, we help confirm prescription details with the prescriber. Dispensing and fulfilment are handled by licensed third-party pharmacies, where permitted. Some patients explore cash-pay options and cross-border fulfilment depending on eligibility and jurisdiction.
Where long-acting insulin fits in care
Basal insulin replaces the body’s background insulin. It is essential in type 1 diabetes and often used in type 2 when oral or injectable non-insulin medicines are not enough. The goal is stable fasting and overnight glucose, with fewer highs and lows.
Care teams individualize targets. They consider hypoglycemia risk, kidney or liver disease, pregnancy, work schedules, and other medicines. Many patients also use mealtime insulin, GLP-1 receptor agonists, or SGLT2 inhibitors. Continuous glucose monitoring can support safer titration, but finger-stick testing remains common and effective when used consistently.
Insulin degludec at a glance
Insulin degludec is a very long-acting basal insulin designed for once-daily use. It forms a subcutaneous depot that releases insulin slowly for more than a full day. This profile supports relatively stable background coverage and some flexibility in dosing time, as determined by the prescriber’s plan.
It is available in multiple strengths (for example, U-100 and U-200 pens). Both deliver insulin in “units” that are dose-equivalent. Patients should not convert between strengths on their own. Pen devices meter the correct amount for that formulation.
Insulin degludec (marketed as Tresiba) is approved for adults and, in many regions, for some children. Age cutoffs and device options can vary by country. It is not for treating diabetic ketoacidosis and is not used in insulin pumps. Do not mix it with other insulins in the same syringe.
Starting and adjusting therapy
Dosing is individualized. The following outlines common clinical approaches used by many teams:
- Type 2 diabetes, insulin-naïve: Clinicians often start at a low once-daily dose, such as 10 units or weight-based dosing around 0.1–0.2 units/kg. The dose is then adjusted based on fasting readings and hypoglycemia risk.
- Type 1 diabetes: Basal insulin is one part of a total daily insulin plan that also includes mealtime insulin. The basal fraction often represents about one-third to one-half of the total daily dose, individualized by the care team.
- Switching from another basal: Many clinicians use a unit-for-unit approach when moving from another once-daily basal insulin. Some reduce the dose when switching from twice-daily NPH or more concentrated formulations. Plans differ by patient history and risk.
- Titration: Stepwise algorithms are common. For example, adjusting by small amounts (such as 2 units) every few days until fasting glucose aligns with the agreed target. Any low readings usually prompt a reduction. The exact schedule should follow the prescriber’s instructions.
Frequent monitoring supports safe titration. Patients with kidney disease, liver disease, irregular meals, or fluctuating activity may need slower adjustments. Any episode of unexplained hypoglycemia warrants a reassessment of dose, timing, injection sites, and possibly other medicines.
Safety, interactions, and contraindications
All insulins carry a risk of hypoglycemia. The immediate risks are loss of alertness, falls, seizures, and injury. Patterns of low glucose need investigation. Review meals, alcohol use, activity, and other drugs. Carry fast-acting carbohydrates if recommended by your care team. Severe hypoglycemia is a medical emergency.
- Common effects: Hypoglycemia, injection site reactions, mild weight gain, and edema.
- Less common: Allergic reactions, lipodystrophy at injection sites, and hypokalemia.
- Not indicated: Treatment of diabetic ketoacidosis. DKA requires rapid-acting insulin protocols and urgent care.
- Drug interactions: Beta-blockers can mask hypoglycemia warning signs. Diuretics and some bronchodilators may affect potassium. Steroids and some antipsychotics can raise glucose. GLP-1 receptor agonists may lower insulin needs. SGLT2 inhibitors can be linked to euglycemic DKA in specific contexts; teams monitor closely when these are combined.
- Special populations: Pregnancy, breastfeeding, advanced age, renal or hepatic impairment, and those with irregular meal patterns require careful planning and close follow-up.
Pen needles and vials are single-patient items. Do not share devices or needles to avoid infection risk. Report persistent skin reactions, generalized rash, or swelling to your clinician.
Practical use: devices, timing, and storage
Basal insulin is injected into fatty tissue, typically the abdomen, thigh, or upper arm. Rotate sites to reduce skin changes. Use a new needle for each injection and dispose of sharps safely. Never extract insulin from a pen with a syringe.
- Timing: Many patients inject at the same time each day. Insulin degludec’s long action allows some timing flexibility, but spacing between doses and the daily schedule should follow the prescriber’s plan. Do not double doses after a missed dose.
- Strengths and increments: Pens may differ in dose increments and maximum dialable units. Review your device’s instructions during training.
- Storage: Unopened insulin is usually refrigerated. In-use pens can often be kept at room temperature for a defined period per the device label. Avoid extreme heat, cold, and direct sunlight.
- Travel and routines: Time zone changes and variable work shifts may require dose-time adjustments. Plan ahead with your care team, and carry backup supplies.
Access, coordination, and documentation
Basal insulin therapy relies on clear documentation and communication. Prescriptions should specify the insulin name, strength, device type, dose, timing instructions, and needle size if needed. Pharmacists, educators, and clinicians share roles in training, dose-review, and follow-up.
In some regions, prescription referral platforms connect these steps across systems and jurisdictions. Their role is administrative and logistical, not clinical decision-making. As one example, CanadianInsulin.com is a prescription referral platform. Where required, we help confirm prescription details with the prescriber. Dispensing and fulfilment are handled by licensed third-party pharmacies, where permitted. Some patients explore cash-pay options and cross-border fulfilment depending on eligibility and jurisdiction. An informational overview, What Is Tresiba: Uses, Dosage, and Side Effects Guide, provides background context on indications, dosing frameworks, and safety points.
Medical disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice. Always seek individualized guidance from a qualified healthcare professional.
Summary
Insulin degludec is a long-acting basal insulin used to stabilize background glucose in type 1 and type 2 diabetes. Its extended activity supports once-daily dosing when clinically appropriate. Safe use depends on individualized starting doses, careful titration, attention to hypoglycemia risk, and sound injection technique. Clear documentation and coordinated workflows help patients, clinicians, and pharmacies support consistent, safe therapy across settings.